Citation:Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, et al 2010

From Cancer Guidelines Wiki

Citation


Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010 Jul;11(7):619-26 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/20570559.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
What is the optimal systemic therapy for stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted

Compare quality appraisals for each clinical question

Cited by

  1. What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?
  2. What is the optimal systemic therapy for stage IV inoperable NSCLC?